These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29440007)

  • 1. Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.
    Torok RD; Li JS; Kannankeril PJ; Atz AM; Bishai R; Bolotin E; Breitenstein S; Chen C; Diacovo T; Feltes T; Furlong P; Hanna M; Graham EM; Hsu D; Ivy DD; Murphy D; Kammerman LA; Kearns G; Lawrence J; Lebeaut B; Li D; Male C; McCrindle B; Mugnier P; Newburger JW; Pearson GD; Peiris V; Percival L; Pina M; Portman R; Shaddy R; Stockbridge NL; Temple R; Hill KD
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29440007
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric cardiovascular drug trials, lessons learned.
    Li JS; Cohen-Wolkowiez M; Pasquali SK
    J Cardiovasc Pharmacol; 2011 Jul; 58(1):4-8. PubMed ID: 21242809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological prevention of cardiovascular diseases].
    Okovityĭ SV; Kulikov AN; Shulenin KS
    Eksp Klin Farmakol; 2011; 74(11):43-7. PubMed ID: 22288160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are the pleiotropic effects of drugs used for the prevention of cardiovascular disease clinically relevant?
    Elisaf M; Liberopoulos EN
    Curr Pharm Des; 2009; 15(5):463-6. PubMed ID: 19199974
    [No Abstract]   [Full Text] [Related]  

  • 5. Seeking Similarities Rather Than Differences With Adults to Aid in Therapeutic Advancement for Children.
    Becker ML; Kraft WK
    Clin Pharmacol Ther; 2021 Jul; 110(1):11-14. PubMed ID: 34148235
    [No Abstract]   [Full Text] [Related]  

  • 6. Orphan Drug Development in Cardiovascular Medicine.
    Khan MS; Vaduganathan M; Butler J
    Circ Cardiovasc Qual Outcomes; 2020 Jul; 13(7):e006509. PubMed ID: 32552063
    [No Abstract]   [Full Text] [Related]  

  • 7. New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017.
    Ollivier C; Sun H; Amchin W; Beghetti M; Berger RMF; Breitenstein S; Garnett C; Gullberg N; Hassel P; Ivy D; Kawut SM; Klein A; Lesage C; Migdal M; Nije B; Odermarsky M; Strait J; de Graeff PA; Stockbridge N
    J Am Heart Assoc; 2019 May; 8(10):e011306. PubMed ID: 31088189
    [No Abstract]   [Full Text] [Related]  

  • 8. All about clinical trial course: one of the masterpieces of the European Society of Cardiology-Working Group on Cardiovascular Pharmacotherapy educational programme.
    Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):275-276. PubMed ID: 32584980
    [No Abstract]   [Full Text] [Related]  

  • 9. Time to welcome the elderly into clinical trials.
    Farkouh ME; Fuster V
    Nat Clin Pract Cardiovasc Med; 2008 Nov; 5(11):673. PubMed ID: 18949002
    [No Abstract]   [Full Text] [Related]  

  • 10. Pediatric hypertension.
    Kay JD; Sinaiko AR; Daniels SR
    Am Heart J; 2001 Sep; 142(3):422-32. PubMed ID: 11526354
    [No Abstract]   [Full Text] [Related]  

  • 11. Organs-on-chip models for cardiovascular drug development.
    Zimmermann WH
    Cardiovasc Res; 2021 Nov; 117(12):e164-e165. PubMed ID: 34347045
    [No Abstract]   [Full Text] [Related]  

  • 12. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN).
    Hare JM; Bolli R; Cooke JP; Gordon DJ; Henry TD; Perin EC; March KL; Murphy MP; Pepine CJ; Simari RD; Skarlatos SI; Traverse JH; Willerson JT; Szady AD; Taylor DA; Vojvodic RW; Yang PC; Moyé LA;
    Circulation; 2013 Apr; 127(15):1630-5. PubMed ID: 23588961
    [No Abstract]   [Full Text] [Related]  

  • 14. Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.
    Tan SS; Rutten FF; Hakkaart-van Roijen L
    J Eval Clin Pract; 2011 Dec; 17(6):1094-101. PubMed ID: 21040249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Summary of the multidisciplinary guideline on cardiovascular risk management (revision 2011)].
    Wiersma T; Smulders YM; Stehouwer CD; Konings KT; Lanphen J
    Ned Tijdschr Geneeskd; 2012; 156(36):A5104. PubMed ID: 22951134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Seltzer J; Turner JR; Anderson JL; Hiatt WR; Kowey P; Prochaska JJ; Stockbridge N; White WB
    Am Heart J; 2015 Apr; 169(4):486-95. PubMed ID: 25819855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
    Czernichow S; Knol MJ; Fezeu L; Grobbee DE
    Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The blood pressure measurement--revisited.
    Safar ME; Smulyan H
    Am Heart J; 2006 Sep; 152(3):417-9. PubMed ID: 16923406
    [No Abstract]   [Full Text] [Related]  

  • 19. The next 10 years in personalized medicine in cardiology.
    Tantry US; Gurbel PA
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):933-5. PubMed ID: 23984921
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations.
    Hallén J; Sreeharan N
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):237-242. PubMed ID: 30060063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.